PriceTargets.com logo

Indaptus Therapeutics - INDP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 694.39%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.07 As of 11/20/2024 01:00 AM ET
▲ +0.04 (3.88%)

This chart shows the closing price for INDP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Indaptus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INDP

Analyst Price Target is $8.50
▲ +694.39% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Indaptus Therapeutics in the last 3 months. The average price target is $8.50, with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 694.39% upside from the last price of $1.07.

This chart shows the closing price for INDP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Indaptus Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024Maxim GroupLower TargetBuy ➝ Buy$8.00 ➝ $5.00
10/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
6/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
9/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
3/20/2023HC WainwrightLower Target$15.00 ➝ $12.00
3/8/2023HC WainwrightReiterated RatingOverweight$15.00
2/8/2023HC WainwrightReiterated RatingBuy$15.00
1/31/2022HC WainwrightReiterated RatingBuy$15.00
10/19/2021Maxim GroupUpgradeHold ➝ Buy$16.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

-0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Indaptus Therapeutics logo
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $1.07
Low: $1.03
High: $1.08

50 Day Range

MA: $1.29
Low: $1.03
High: $1.91

52 Week Range

Now: $1.07
Low: $1.02
High: $3.10

Volume

11,840 shs

Average Volume

62,921 shs

Market Capitalization

$10.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Indaptus Therapeutics?

The following equities research analysts have issued research reports on Indaptus Therapeutics in the last twelve months: HC Wainwright, and Maxim Group.
View the latest analyst ratings for INDP.

What is the current price target for Indaptus Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Indaptus Therapeutics in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 694.4%. HC Wainwright has the highest price target set, predicting INDP will reach $12.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $5.00 for Indaptus Therapeutics in the next year.
View the latest price targets for INDP.

What is the current consensus analyst rating for Indaptus Therapeutics?

Indaptus Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INDP will outperform the market and that investors should add to their positions of Indaptus Therapeutics.
View the latest ratings for INDP.

What other companies compete with Indaptus Therapeutics?

Other companies that are similar to Indaptus Therapeutics include BioLineRx, Actinium Pharmaceuticals, VYNE Therapeutics, Rallybio and Reviva Pharmaceuticals. Learn More about companies similar to Indaptus Therapeutics.

How do I contact Indaptus Therapeutics' investor relations team?

Indaptus Therapeutics' physical mailing address is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. The company's listed phone number is (646) 427-2727 and its investor relations email address is [email protected]. The official website for Indaptus Therapeutics is intecpharma.com. Learn More about contacing Indaptus Therapeutics investor relations.